BioAge Labs News

BioAge Labs, Inc. (BIOA): A Bull Case Theory

Yahoo FinanceDec 27 09:18 ET

Hunterbrook Capital Long Bioage Labs, Hunterbrook Media Reports

TipRanksDec 20 12:35 ET

BioAge Stock Advances 14% On Novartis Research Collaboration

WSJDec 18 10:21 ET

BioAge Labs Says It Is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases

MT NewswiresDec 18 09:50 ET

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

BioAge LabDec 18 09:10 ET

Express News | Bioage Labs Inc - May Receive up to $530M in Future Milestones

ReutersDec 18 09:02 ET

BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman

newsfileDec 13 15:31 ET

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More

Zacks Dec 11 09:05 ET

Morgan Stanley Downgrades BioAge Labs to Underweight From Overweight, Slashes Price Target to $5 From $40

MT NewswiresDec 10 06:22 ET · Ratings

Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday

BenzingaDec 9 10:04 ET

Express News | Bioage Labs Falls 76.9% After Jefferies Cuts PT on Co

ReutersDec 9 09:37 ET

Traders Eye Key Inflation Report as US Equity Futures Waver Pre-Bell

MT NewswiresDec 9 08:47 ET

BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BenzingaDec 9 08:20 ET

Express News | BioAdge Labs Shares Are Trading Lower After Jefferies Downgraded the Stock From Buy to Hold and Citigroup Downgraded the Stock From Buy to Neutral. Additionally, Both Firms Cut Their Price Target on the Stock to $7

BenzingaDec 9 08:14 ET

Top Premarket Decliners

MT NewswiresDec 9 07:41 ET

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

BenzingaDec 9 07:41 ET

Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45

MT NewswiresDec 9 07:28 ET · Ratings

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination With Tirzepatide for the Treatment of Obesity

InvestingDec 9 07:20 ET

Morgan Stanley Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsDec 9 06:31 ET · Ratings

BioAge Shares Slide Premarket After Obesity Study Halted for Safety

WSJDec 9 06:28 ET